There have been no reports on the effects of teneligliptin compared to sitagliptin in terms of protective effects on vascular endothelial function, suppression of oxidative stress, and effect on biomarkers of tubulointerstitial kidney damage such as liver fatty acid-binding protein (L-FABP) [13] in patients with type 2 diabetes and CKD. This evidence concerns the gene FABP1 and type 2 diabetes mellitus.